Deeptech Bpifrance Microbiome
Aug 12, 2019

Exeliom Biosciences is awarded 1.8M€ DeepTech grant from Bpifrance to advance its lead program

Bpifrance awarded Exeliom Biosciences with a 1.8M€ grant to accelerate the development of its lead candidate EXL01, a Live Biotherapeutics Products (LBP) to fight Crohn's Disease.

This support from Bpifrance will help Exeliom Biosciences tackle the two main challenges ahead: 1) building a regulatory dossier for EXL01 to secure a first clinical trial authorization in an emerging regulatory category, and 2) scaling-up the manufacturing process to clinical-scale. 

Back to news


Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.